title: Systemic therapy for advanced pancreatic neuroendocrine tumors.
abstract: Neuroendocrine tumors (NETs) occur throughout the body, and share similar histologic characteristics. However, it has become increasingly evident that pancreatic NETs tend to respond differently to therapeutic agents than do other NET subtypes. In most cases, systemic therapy has been more effective in NETs of pancreatic origin than in NETs arising from other locations. Traditional systemic treatment options for pancreatic NETs include somatostatin analogs or cytotoxic chemotherapy. Recently, the biologically targeted agents everolimus and sunitinib were approved for use in patients with metastatic disease. Novel agents, as well as novel drug combinations, are currently under investigation.
authors: Program in Neuroendocrine and Carcinoid Tumors, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. Matthew_Kulke@dfci.harvard.edu
authors: Matthew H
authors: MH
authors: Kulke
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000068338:Everolimus; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D007211:Indoles; D011758:Pyrroles; D013004:Somatostatin; D000068338:Everolimus; D000077210:Sunitinib; D020123:Sirolimus
references: Ann Oncol. 2002 Apr;13(4):614-21
references: 12056713
references: Cancer Cell. 2002 Mar;1(2):193-202
references: 12086877
references: Neuroendocrinology. 2009;90(1):67-72
references: 19521065
references: J Clin Oncol. 2007 Apr 20;25(12):1470-5
references: 17442989
references: Cancer. 1991 Feb 1;67(3):547-9
references: 1702352
references: Cancer. 1999 Sep 15;86(6):944-8
references: 10491519
references: Clin Gastroenterol Hepatol. 2005 Aug;3(8):761-71
references: 16234004
references: J Clin Oncol. 2010 Jan 10;28(2):245-55
references: 19917848
references: N Engl J Med. 2011 Feb 10;364(6):501-13
references: 21306237
references: J Nucl Med. 2011 Sep;52(9):1361-8
references: 21795361
references: Cancer. 2011 Jan 15;117(2):268-75
references: 20824724
references: Br J Cancer. 2006 Nov 6;95(9):1148-54
references: 17031397
references: Endocr Pathol. 2007 Summer;18(2):79-85
references: 17916997
references: J Clin Oncol. 2010 Apr 1;28(10):1652-9
references: 20194865
references: Clin Cancer Res. 2009 Jan 1;15(1):338-45
references: 19118063
references: J Clin Oncol. 2008 May 1;26(13):2124-30
references: 18445841
references: J Clin Oncol. 2011 Jun 10;29(17):2416-23
references: 21555692
references: Cancer Chemother Pharmacol. 2007 Apr;59(5):637-42
references: 16937105
references: Pancreas. 2009 Oct;38(7):811-4
references: 19657309
references: Clin Cancer Res. 2007 May 15;13(10):2986-91
references: 17505000
references: J Clin Oncol. 2012 Apr 1;30(10):1100-6
references: 22393097
references: Science. 2011 Mar 4;331(6021):1199-203
references: 21252315
references: J Clin Oncol. 2006 Oct 10;24(29):4746-53
references: 16954518
references: J Clin Oncol. 2003 Jul 15;21(14):2689-96
references: 12860945
references: N Engl J Med. 2011 Feb 10;364(6):514-23
references: 21306238
references: Cancer. 2002 Jan 15;94(2):331-43
references: 11900219
references: N Engl J Med. 2005 Mar 10;352(10):997-1003
references: 15758010
references: N Engl J Med. 1984 Mar 22;310(12):758-61
references: 6142418
references: N Engl J Med. 1983 Jul 21;309(3):129-33
references: 6191217
references: Intern Med J. 2007 Jun;37(6):406-9
references: 17535385
references: Acta Oncol. 1993;32(2):235-8
references: 7686766
references: J Clin Oncol. 2006 Jan 20;24(3):401-6
references: 16421420
references: Cancer Invest. 2007 Jun;25(4):249-55
references: 17612935
references: J Clin Oncol. 1998 Dec;16(12):3851-7
references: 9850030
references: J Clin Oncol. 2002 May 1;20(9):2388-99
references: 11981013
references: J Clin Oncol. 2004 Dec 1;22(23):4762-71
references: 15570077
references: J Clin Oncol. 2008 Sep 10;26(26):4311-8
references: 18779618
references: Br J Cancer. 1998 Nov;78(9):1199-202
references: 9820180
references: Endocrinol Metab Clin North Am. 2011 Mar;40(1):19-63, vii
references: 21349410
references: J Clin Oncol. 2008 Jul 10;26(20):3403-10
references: 18612155
references: Cancer. 2007 Apr 15;109(8):1478-86
references: 17340592
references: N Engl J Med. 2009 Jan 8;360(2):195-7
references: 19129539
references: Mol Cell Endocrinol. 2008 May 14;286(1-2):69-74
references: 17977644
references: J Clin Oncol. 2010 Jan 1;28(1):69-76
references: 19933912
references: Am J Clin Oncol. 2004 Oct;27(5):485-8
references: 15596916
references: Cancer Res. 1987 Nov 15;47(22):5846-52
references: 3664486
references: Cancer Metastasis Rev. 2011 Mar;30 Suppl 1:27-34
references: 21311955
references: Endocrinol Metab Clin North Am. 2011 Mar;40(1):173-85, ix
references: 21349418
references: Acta Oncol. 1991;30(4):519-22
references: 1854509
references: Endocr Relat Cancer. 2003 Dec;10(4):451-8
references: 14713257
references: Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35
references: 21157483
references: Pancreas. 2009 Apr;38(3):255-8
references: 19066493
references: Ann Oncol. 2001 Aug;12(8):1139-43
references: 11583197
references: N Engl J Med. 1992 Feb 20;326(8):519-23
references: 1310159
references: J Clin Oncol. 2009 Oct 1;27(28):4656-63
references: 19704057